ATC Group: A10BF02 Miglitol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BF02 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BF Alpha glucosidase inhibitors
5 A10BF02 Miglitol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.3 g

Active ingredients in A10BF02

Active Ingredient Description

Miglitol is a reversible inhibitor of intestinal alpha-glucosidases. Under the influence of miglitol, the digestion of complex carbohydrates into absorbable monosaccharides in the small intestine is dosedependently delayed. Administration of miglitol thus leads to reduced postprandial hyperglycaemia and a smoothing effect on fluctuations in the daily blood glucose profile.

Medicines in this ATC group

Japan (JP)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.